source
- Early-stage data show promise for targeting Wnt/β-catenin pathway across cancersEarly-stage clinical results from the company and several peers indicate that the Wnt/β-catenin signaling pathway could become a viable target for treating a range of tumor types. The pathway has…
- Setara Biosciences launches with $90 million to pursue Charcot-Marie-Tooth and other rare-disease therapiesSetara Biosciences announced its formation on Friday, backed by $90 million of financing to advance a pipeline of experimental medicines. The company’s first candidate targets the genetic disorder…